Thermostable vaccine technology platform to be presented at the 6th international conference on vaccines research and development

Princeton, n.j., nov. 1, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that oreola donini, phd, chief scientific officer, will be presenting key data from the company's thermostable vaccine technology platform, including results from the company's programs for ricin toxin vaccine (rivax® ), covid-19 vaccine (civax™) and filovirus vaccines (targeting ebola, sudan, and marburg viruses).
SNGX Ratings Summary
SNGX Quant Ranking